Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page.

General Instructions provides useful general background information for successfully completing forms.

2804/2814: CRID Assignment and Indication provides explanatory text used to generate a CIBMTR Research ID (CRID) and report the indication.

Transplant Essential Data (TED) Manuals provides explanatory text for each question found on the TED forms.

Comprehensive Baseline & Follow-up Forms Manuals provides explanatory text for each question on the Baseline, Follow-up, IDMs, HLA, and Infusion forms.

Comprehensive Disease Specific Manuals provides explanatory text and additional information for disease indications requiring CIBMTR reporting.

Cellular Therapy Manuals provides explanatory text for completing pre-infusion, infusion, and post-infusion forms

Infection & Miscellaneous Manuals provides explanatory text for manuals such as the Hepatitis Serology, VOD / SOS, and Myelofibrosis CMS Study forms.

Appendices provide additional information beyond the scope of the other manuals.

Manual Updates:
Sections of the Forms Instruction Manual are frequently updated. In addition to documenting the changes within each manual section, the most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

Date Manual Section Add/Remove/Modify Description
5/21/18 2400: Pre-TED Modify Added (in red below) and removed (struck out below) text from the instructions for reporting comorbidities (questions 98-134).
Arrhythmia: Any history of any type of arrhythmia that has necessitated the delivery of a specific antiarrhythmic agent. Examples include, but are not limited to, atrial fibrillation or flutter, sick sinus syndrome, or and ventricular arrhythmias requiring treatment.
Cardiac: Any history of coronary artery disease (one or more vessel coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure, myocardial infarction, and / or ejection fraction ≤ 50% (shortening fraction < 26 for pediatric recipients)% on the most recent test.
Cerebrovascular disease: Any history of transient ischemic attack, subarachnoid hemorrhage, and / or cerebrovascular accident cerebral thrombosis embolism, or hemorrhage.
Diabetes: Diabetes or steroid-induced hyperglycemia requiring continuous treatment with insulin or oral hypoglycemics in the last 4 weeks. but not diet alone
Heart valve disease: Moderate or severe valve stenosis or insufficiency (mitral, aortic, tricuspid, or pulmonary) as determined by echocardiogram, prosthetic mitral or aortic valve, and / or symptomatic mitral valve prolapse. Except asymptomatic mitral prolapse.
Psychiatric disturbance: The presence of any mood, anxiety, or other psychiatric disorder requiring continuous treatment during the last four weeks. Examples include, but are not limited to, depression, anxiety, bipolar disorder, or and schizophrenia requiring psychiatric treatment in the last 4 weeks.
Pulmonary (moderate): Corrected diffusion capacity of carbon monoxide (e.g., DLCOc, DLCOcorr, DLCO) and/or FEV1 66-80% or dyspnea on slight activity at transplant. Use the Dinakara equation below to determine the DLCOc if only an uncorrected value is provided. For recipients assessed by a postbronchodilator test, only the prebronchodilator FEV1 values are considered for evaluation of pulmonary comorbidity.
Dinakara Equation: DLCOc = {uncorrected DLCO} / [0.06965 x {hemoglobin g/dL}]
Pulmonary (severe): Corrected diffusion capacity of carbon monoxide (e.g., DLCOc, DLCOcorr, DLCO) and/or FEV1 ≤ 65% or dyspnea at rest or requiring oxygen at transplant. Use the Dinakara equation above to determine the DLCOc if only an uncorrected value is provided. or recipients assessed by a postbronchodilator test, only the prebronchodilator FEV1 values are considered for evaluation of pulmonary comorbidity.
Renal (moderate/severe): Serum creatinine > 2 mg/dL or > 176.8 177 μmol/L, or on dialysis at transplant, or prior renal transplantation. See note in question 97.
5/10/18 2100: Post-HCT Follow-Up Add Added Fecal Microbiota Transplant note box to acute (questions 185-233) and chronic (questions 328-399) GVHD treatment instructions.
5/10/18 LYM Response Criteria Add Added “Relapsed Disease” to “Progressive Disease” criteria and included clarification on when to report these disease status.
5/7/18 2553: VOD/SOS Add Added an example on how to report the planned total daily dose for Defibrotide
5/7/18 2400: Pre-TED Modify Modified language on how to report Drugs After Transplant, replaced “day 0” with “transplant” to clarify how to report drugs planned for day 0
5/7/18 2400: Pre-TED Add Added note box to capture all comorbidities including those that are considered complications of the primary disease for transplant and provided examples
5/1/18 2150: Viral Infections Add Version 1 of the 2150: Viral Infections section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2150.
5/1/18 2046: Fungal Infection Pre-Infusion Data Modify Version 2 of the 2046: Fungal Infection Pre-Infusion Data section of the Forms Instructions Manual released. Version 2 corresponds to revision 5 of the Form 2046.
5/1/18 2146: Fungal Infection Post-Infusion Data Modify Version 2 of the 2146: Fungal Infection Post-Infusion Data section of the Forms Instructions Manual released. Version 2 corresponds to revision 4 of the Form 2146.
5/1/18 2565: Sanofi Mozobil Supplemental Data Collection Add Version 1 of the 2565: Sanofi Mozobil Supplemental Data Collection section of the Forms Instruction Manual released. Version 1 corresponds to revision 1 of the Form 2565.
4/30/18 2450: Post-TED Add Added the following instruction for question 34. Please note, questions 35 and 36 must still be answered if question 34 is reported as “unknown.”
4/30/18 2450: Post-TED Modify Updated language on how to report the “Date of most recent disease assessment” for questions 237-238: current disease status.
4/23/18 2018: LYM Pre-Infusion Data Modify Corrected errors in the instruction manual by adding (in red below) and removing (struck out below) text to the instructions for questions 269-272, 273-276, and 277-280.
Indicate the result of [method] testing performed at the last evaluation prior to the start of the preparative regimen / infusion. If testing was “Positive,” or “Negative,” report the sample source in questions [question numbers]…
If all [method] testing was negative or testing was not done at the last evaluation prior to the start of the preparative regimen, report “Negative” or “Not done” respectively
4/20/18 Appendix M: Critical Data Fields Modify New version of Appendix M: Critical Data Fields of the Forms Instructions Manual released. Note, prior versions of this appendix were referred to as Appendix Y: Critical Data Fields.
4/20/18 4003: Cellular Therapy Product Add Added Cryopreservation as a Manipulation note box to the instructions for questions 31-32.
4/16/18 2000: Recipient Baseline Add Added Fungal Infection Diagnosis Reporting Scenario to the instructions for question 57.
4/10/18 2402: Disease Classification Modify Updated the Common Disease Transformation Table included in the instructions for questions 1 and 2. The CLL section of the form should not be completed for a Richter’s Transformation as of Revision 3 of the Form 2402.
4/10/18 4006: Cellular Therapy Infusion Add Added in additional clarification regarding total cell counts administered, what constitutes unselected lymphocytes, and T-helper cells (Q17-24).
4/9/18 2402: Disease Classification Modify Modified the following instruction for question 317:
Enter the date of the most recent assessment of disease status prior to the start of the preparative regimen. Report the date the blood/urine was collected for the laboratory evaluations (e.g., SPEP/UPEP, serum/urine immunofixation) or report the date the bone marrow was collected for pathological evaluation. A PET scan Date of radiographic study (PET, MRI, CT) may be used if the same a previous PET scan radiographic study had previously been obtained and only in limited circumstances (e.g., plasmacytomas, lytic lesions).

Feedback

Was this helpful?

Yes No
You indicated this topic was not helpful to you ...
Could you please leave a comment telling us why? Thank you!
Thanks for your feedback.

Post your comment on this topic.

Please do not use this for support questions.
For customer support, please contact us here.

Post Comment